Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Sees Significant Decrease in Short Interest

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 199,838 shares, a decline of 65.2% from the July 15th total of 574,897 shares. Approximately 5.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,642,637 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Catheter Precision stock. Millennium Management LLC purchased a new stake in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent filing with the Securities & Exchange Commission. 20.34% of the stock is currently owned by institutional investors and hedge funds.

Catheter Precision Trading Down 5.9%

NYSEAMERICAN VTAK traded down $0.02 on Friday, hitting $0.27. 500,612 shares of the company were exchanged, compared to its average volume of 4,577,982. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06. Catheter Precision has a twelve month low of $0.23 and a twelve month high of $4.31. The firm has a market capitalization of $985,530.00, a P/E ratio of -0.02 and a beta of -1.00. The company’s 50 day moving average price is $0.68 and its 200-day moving average price is $1.05.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($20.90) by $19.51. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.60 million.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.